TENX Tenax Therapeutics Inc.

0.59
-0.04  -7%
Previous Close 0.63
Open 0.63
Price To Book 1.18
Market Cap 4,488,863
Shares 7,608,243
Volume 346,558
Short Ratio
Av. Daily Volume 139,377
Stock charts supplied by TradingView

NewsSee all news

  1. Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 "HELP Study" of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

    Top-line Data Readout Remains on Track for Late Q2 2020 Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address

  2. Tenax Therapeutics Completes Enrollment in Phase 2 Pulmonary Hypertension Trial

    HELP study exceeds target enrollment with 37 patients 84% initial open-label lead-in response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced, on average, by 7.5 mmHg during

  3. Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market

    Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or the "Company"), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases

  4. Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board

    Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,

  5. Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

    24 patients have been randomized 86% initial response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced, on average, by 7.6 mmHg during exercise following the initial

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due late-2Q 2020.
Levosimendan
Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF)
Phase 2b trial did not meet primary endpoint.
Levosimendan
Septic shock
Phase 3 top line data released January 31, 2017 - primary endpoints not met. Met with FDA May 10, 2017 to discuss potential NDA submission.
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery

Latest News

  1. Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 "HELP Study" of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

    Top-line Data Readout Remains on Track for Late Q2 2020 Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address

  2. Tenax Therapeutics Completes Enrollment in Phase 2 Pulmonary Hypertension Trial

    HELP study exceeds target enrollment with 37 patients 84% initial open-label lead-in response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced, on average, by 7.5 mmHg during

  3. Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market

    Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or the "Company"), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases

  4. Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board

    Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,

  5. Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

    24 patients have been randomized 86% initial response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced, on average, by 7.6 mmHg during exercise following the initial

  6. Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

    15 patients have been randomized 83% initial response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced , on average, by 8 mmHg during exercise following the initial

  7. Tenax Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference

    Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,

  8. Tenax Therapeutics Provides Clinical Development Update

    Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,